Skip to main
IGC
IGC logo

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma Inc is developing innovative cannabinoid-based formulations with investigational drug assets, particularly targeting Alzheimer's disease, which exhibit potential efficacy in combating key disease hallmarks. The company's current valuation reflects an attractive investment opportunity, highlighted by a notable increase in price target based on a net present value analysis, suggesting substantial upside from the existing share price. Additionally, upcoming positive data and advancements in the company’s research are anticipated to act as catalysts to further enhance stock performance.

Bears say

IGC Pharma Inc reported a net loss of $1.6 million, resulting in an earnings per share (EPS) of $(0.02), which aligns with both the company's and consensus estimates but indicates ongoing financial challenges. Key risks impacting IGC Pharma's outlook include significant balance sheet and liquidity concerns, potential failures in demonstrating the safety and efficacy of its investigational drug candidates, and hurdles related to regulatory approvals, commercialization, and reimbursement. Additionally, increased competition, fluctuating macroeconomic conditions, and changing investor sentiment towards biotech stocks further compound the negative outlook for the company's stock.

IGC has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 2 analysts, IGC has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.